We are live on ! Find out more
STML

Stemline Therapeutics, Inc.
STML

Delisted

STML was delisted on the 9th of June, 2020.

Back to rankings

61 hedge funds and large institutions have $172M invested in Stemline Therapeutics, Inc. in 2014 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 25 increasing their positions, 15 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 15

5% more capital invested

Capital invested by funds: $163M → $172M (+$8.31M)

12% less funds holding

Funds holding: 69 → 61 (-8)

53% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 15

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
61
Holders Change
-8
Holders Change %
-11.59%
% of All Funds
1.76%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
7
Increased
25
Reduced
15
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TCM
TimesSquare Capital Management
New York
+$19.7M
2
Franklin Resources
Franklin Resources
California
+$9.01M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$4M
4
EAM
Eventide Asset Management
Massachusetts
+$3.74M
5
PCA
Private Capital Advisors
Connecticut
+$3.2M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$8.16M
2
SCA
SAC Capital Advisors
Connecticut
-$7.55M
3
Jennison Associates
Jennison Associates
New York
-$2.69M
4
DCM
Driehaus Capital Management
Illinois
-$1.85M
5
SM
Sabby Management
Florida
-$1.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
51
BlackRock
New York
$7K +$1.84K +76 +29%
MTIP
52
Magee Thomson Investment Partners
California
$6K – – –
BJ
53
BlackRock Japan
Japan
$6K +$5.63K +232 +407%
AllianceBernstein
54
AllianceBernstein
Tennessee
$5K +$5.36K +221 +1,163%
PNC Financial Services Group
55
PNC Financial Services Group
Pennsylvania
$4K -$24.3K -1,000 -83%
SSG
56
Summit Securities Group
New York
$4K +$4.85K +200 New
PA
57
Perceptive Advisors
New York
$1K – – –
Manulife (Manufacturers Life Insurance)
58
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$156 +$5.99K +247 +3%
RCI
59
Ridgeback Capital Investments
Florida
– -$9.93M -506,699 Closed
Jennison Associates
60
Jennison Associates
New York
– -$2.69M -137,186 Closed
DCM
61
Driehaus Capital Management
Illinois
– -$1.85M -94,273 Closed
SM
62
Sabby Management
Florida
– -$1.33M -68,100 Closed
SCM
63
Sigma Capital Management
Connecticut
– -$1.18M -60,000 Closed
Two Sigma Investments
64
Two Sigma Investments
New York
– -$696K -35,524 Closed
Lazard Asset Management
65
Lazard Asset Management
New York
– -$634K -32,350 Closed
NI
66
Numeric Investors
Massachusetts
– -$509K -25,951 Closed
D.E. Shaw & Co
67
D.E. Shaw & Co
New York
– -$431K -22,002 Closed
AGM
68
Alpine Global Management
New York
– -$392K -20,000 Closed
EIM
69
Essex Investment Management
Massachusetts
– -$365K -18,600 Closed
CD
70
Carl Domino
Florida
– -$237K -12,100 Closed
Susquehanna International Group
71
Susquehanna International Group
Pennsylvania
– -$207K -10,568 Closed
Bank of America
72
Bank of America
North Carolina
– -$156K -6,409 -100%
TRCT
73
Tower Research Capital (TRC)
New York
– -$29K -1,470 Closed
BNP Paribas Financial Markets
74
BNP Paribas Financial Markets
France
– -$2.31K -118 Closed
Creative Planning
75
Creative Planning
Kansas
– +$485 +20 New
1 2
3

STML Hedge Fund Activity: Q1 2014 in Review

61 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q1 2014, worth a combined $172M — up 5.1% from $163M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of STML and 7 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 25 added.

The largest buyer was TimesSquare Capital Management, opening a new position worth an estimated $19.7M. The largest seller was Baker Bros. Advisors, cutting an estimated $8.16M.

  • 61 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q1 2014, down from 69 in Q4 2013.
  • Funds reported $172M of Stemline Therapeutics, Inc. stock for Q1 2014, up 5.1% quarter-over-quarter.
  • 7 funds opened new Stemline Therapeutics, Inc. positions in Q1 2014 and 15 closed out, a net change of -8 holders.
  • The largest Stemline Therapeutics, Inc. buyer in Q1 2014 was TimesSquare Capital Management, an estimated $19.7M added.
  • The largest Stemline Therapeutics, Inc. seller in Q1 2014 was Baker Bros. Advisors, an estimated $8.16M sold.

Based on aggregated 13F filings for Q1 2014.